Logo image
Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994-2004
Journal article   Open access   Peer reviewed

Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994-2004

Joseph J. Amon, Richard S. Garfein, Linda Ahdieh-Grant, Gregory L. Armstrong, Lawrence J. Ouellet, Mary H. Latka, David Vlahov, Steffanie A. Strathdee, Sharon M. Hudson, Peter Kerndt, …
Clinical infectious diseases, v 46(12), pp 1852-1858
15 Jun 2008
PMID: 18462109
url
https://doi.org/10.1086/588297View
Published, Version of Record (VoR) Restricted

Abstract

Life Sciences & Biomedicine Science & Technology Immunology Infectious Diseases Microbiology
Objective. To examine hepatitis C virus (HCV) seroprevalence among injection drug users in 4 US cities from 1994 through 2004. Methods. Demographic characteristics, behaviors, and prevalence of HCV antibody among 5088 injection drug users aged 18-40 years from Baltimore, Maryland; Chicago, Illinois; Los Angeles, California; and New York, New York, enrolled in 3 related studies-Collaborative Injection Drug User Study (CIDUS) I (1994-1996), CIDUS II (1997-1999), and CIDUS III/Drug User Intervention Trial (2002-2004)-were compared using the chi(2) and Mantel-Haenszel tests of significance. Trends over time were assessed by logistic regression. Results. Prevalence of HCV infection was 65%, 35%, and 35% in CIDUS I, CIDUS II, and CIDUS III, respectively. The adjusted prevalence odds ratio (OR) of being HCV antibody positive increased with the number of years of injection drug use (OR, 1.93 [95% confidence interval {CI}, 1.68-2.21] for each year of injecting within the first 2 years; OR, 1.09 [95% CI, 1.07-1.11] for each year of injecting beyond the first 2 years). Significant decreases were observed in the prevalence of HCV antibody between CIDUS I and CIDUS III in Baltimore (OR, 0.30; 95% CI, 0.20-0.43) and Los Angeles (OR, 0.17; 95% CI, 0.09-0.31) and among people of races other than black in Chicago (OR, 0.12; 95% CI, 0.08-0.17). No decrease in prevalence was seen in New York (OR, 1.04; 95% CI, 0.69-1.58) or among blacks in Chicago (OR, 0.55; 95% CI, 0.16-1.90). Conclusion. Although regional differences exist, our data suggest that the incidence of HCV infection among injection drug users in the United States decreased from 1994 through 2004.

Metrics

3 Record Views
154 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
Web of Science research areas
Immunology
Infectious Diseases
Microbiology
Logo image